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Abstract
Background: Antidepressants are used both for treating acute episodes and for prophylaxis to prevent future
episodes of depression, also called maintenance treatment. This article describes the protocol for a randomised
controlled trial (ANTLER: ANTidepressants to prevent reLapse in dEpRession) to investigate the clinical effectiveness
and cost-effectiveness in UK primary care of continuing on long-term maintenance antidepressants compared with
a placebo in preventing relapse of depression in those who have taken antidepressants for more than 9 months
and who are currently well enough to consider stopping maintenance treatment.
Methods/design: The ANTLER trial is an individually randomised, double-blind, placebo-controlled trial in which
participants are randomised to remain on active medication or to take an identical placebo after a tapering period
of 2 months. Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two
episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking
citalopram 20mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider
stopping their medication. The participants will be followed up at 6, 12, 26, 39 and 52 weeks.
The primary outcome will be the time in weeks to the beginning of the first episode of depression after
randomisation. This will be measured using a retrospective version of the Clinical Interview Schedule—Revised
administered at 12, 26, 39 and 52 weeks.
Secondary outcomes will include depressive and anxiety symptoms, adverse effects, withdrawal symptoms,
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emotional processing tasks, quality of life and the resources and costs used. We will also perform a cost-
effectiveness analysis based on results of the trial.
Discussion: The ANTLER trial findings will inform primary care prescribing practice by providing a valid and
generalisable estimate of the clinical effectiveness and cost-effectiveness of long-term maintenance treatment with
antidepressants in UK primary care.
Trial registration: Controlled Trials ISRCTN Registry, ISRCTN15969819. Registered on 21 September 2015.
Keywords: Depression, Primary care, Antidepressants, Sertraline, Citalopram, Fluoxetine, Mirtazapine, Selective
serotonin reuptake inhibitors
Background
Depression is a major health problem that is not only
debilitating to the individual but also to society, being
the lead cause of disability worldwide [1]. Globally, more
than 300 million people live with depression. Antide-
pressants are often a first-line treatment for depressive
symptoms and are also used for maintenance treatment;
that is, to prevent relapse once an individual has recov-
ered. It has been estimated that, between 1993 and 2005,
90% of antidepressant prescriptions [2] in the UK were
used for maintenance. A more recent UK study [3] has
also demonstrated a steady increase between 2001 and
2012 in the duration of long-term treatment.
The number of prescriptions for antidepressants has risen
dramatically in recent years; increasing by around 7% per
annum in the UK. Furthermore, antidepressant prescribing
has shown a greater increase than drugs for any other
therapeutic area, with over 65 million prescriptions being
issued in England in 2016, at a cost of £266.6 million to the
NHS [4, 5] Similar increases in antidepressant prescribing
have been observed in other high-income countries [6].
Moreover, there are other considerations in addition
to cost. Prolonged antidepressant treatment has been as-
sociated with common side effects such as weight gain,
sleep disturbance and sexual dysfunction. There are also
reports of an association between antidepressants and
severe adverse outcomes in older people such as stroke
and transient ischaemic attack, although there is no evi-
dence to say that the associations are causal [7].
The National Institute for Health and Care Excellence
(NICE) in England recommends that antidepressant
maintenance treatments should continue to be used for
2 years for those at risk of relapse [8]. However, they also
recognise the uncertainty about the benefit of long-term
maintenance treatment and recommend further research
into its psychological and pharmacological effects.
The impact on relapse rates of continuing mainten-
ance treatment in the first few months after remission
has been achieved with antidepressant treatment has
been extensively studied [9–11]. However, the amount of
evidence for a treatment period longer than 36 weeks is
small. In the existing reviews, there were only three
studies [12–14] that have treated patients for more than
32 weeks. All three had methodological and statistical
limitations due to either small sample size (e.g. Cook et
al. [12], N = 15; Bialos et al. [13], N = 17; and Kupfer et
al. [14], N = 20) or sample characteristics (e.g. Cook et
al. [12] sample compromised elderly males). A further
weakness in the reviewed studies was that most were
funded by the pharmaceutical industry. The pharma-
ceutical companies can be imaginative in ways of ma-
nipulating their research findings [15, 16] and there is
evidence that they publish only half of their trials [17].
The studies were conducted in a variety of different
health systems with antidepressant medication that is
not currently used in the UK. Therefore, the results are
difficult to generalise to the UK population.
There is some evidence that the number of previous
episodes, a presence of residual depressive symptoms
and female gender are associated with increased rates of
relapse. However, there is no evidence that these factors
are associated with the difference in relapse rates be-
tween maintenance antidepressant and placebo.
The long-term benefits of the ANTLER (ANTidepres-
sants to prevent reLapse in dEpRession) trial may lead to
improving treatment recommendations and guidance for
general practitioners (GPs). As there is very limited evi-
dence for effectiveness of maintenance treatment longer
than 6months, the ANTLER trial will refine our under-
standing of the costs and benefits of long-term mainten-
ance therapy and therefore will help to inform patients
and practitioners when treatment decisions regarding the
duration of treatment are being discussed. If the results of
the ANTLER trial demonstrate that long-term mainten-
ance treatment proves ineffective, this will lead to benefits
associated with reducing not only unnecessary treatment
but also adverse effects and costs. On the other hand, if
maintenance treatment proves effective, individuals who
are not currently taking medication to prevent depressive
relapse might benefit from antidepressant use.
The aim of the trial is to answer the following re-
search question: ‘What is the clinical effectiveness and
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cost-effectiveness in UK primary care of continuing
on long-term maintenance antidepressants compared
with a placebo in preventing relapse of depression in
those who have taken antidepressants for more than
9 months and who are now well enough to consider
stopping maintenance treatment?’
The objective of the trial is to provide a valid and gen-
eralisable estimate of the clinical effectiveness and
cost-effectiveness of long-term maintenance treatment
with antidepressants in UK primary care.
The choice of trial medication
The choice of medication was guided by the pragmatics of
recruitment and carrying out the study. We think it is im-
portant to compare the active treatment with a placebo in
a condition such as depression with well-described pla-
cebo effects. Therefore, we wanted to minimise the num-
ber of antidepressants to make the manufacture and
distribution of placebo easier. There are a large number of
antidepressants all of which act on the monoamine sys-
tems, especially serotonin (5-hydroxytryptamine or 5HT)
and noradrenaline. The tricyclic antidepressants are 5HT
and/or noradrenaline reuptake inhibitors, although they
tend also to have other pharmacological actions that in-
crease the side effect burden. The most commonly pre-
scribed antidepressants now are the selective serotonin
reuptake inhibitors (SSRIs): citalopram, escitalopram, ser-
traline, paroxetine and fluoxetine. Other commonly used
antidepressants include venlafaxine, which has both sero-
tonin and noradrenaline reuptake inhibitor (SNRI) proper-
ties. Mirtazapine has a slightly different mode of action
and is described as a noradrenergic and specific serotoner-
gic antidepressant (NaSSA), although the net effect of its
action is to increase serotonergic and to some extent nor-
adrenaline transmission. Use of mirtazapine is increasing
rapidly and accounted for 13% of prescriptions in England
for antidepressants in 2013.
Due to marked pharmacological similarities between the
antidepressants it is usually assumed that they share a
common mode of action and any differences in efficacy
are likely to be relatively minor [18]. Meta-analyses [10,
11] of the different classes of antidepressants have found
no evidence to suggest that the tricyclics, SSRIs and SNRIs
differ in their effectiveness as a maintenance treatment.
We have chosen not to use paroxetine as it has a short
half-life and is associated with a more marked with-
drawal syndrome and might not be tolerated by some in-
dividuals when they are withdrawn after randomisation.
Escitalopram is not widely used in primary care in the
UK and has not been included in many primary care for-
mularies. Venlafaxine tends to be used more by second-
ary care than primary care doctors, can be poorly
tolerated and also has more marked withdrawal effects.
Amitriptyline is often used for treatment of pain and
insomnia, and much less often now as an antidepressant
because it is less well tolerated than SSRIs and poten-
tially more lethal in overdose. Moreover, amitriptyline is
not recommended as a first-line antidepressant—we
have omitted it here.
We will therefore recruit primary care patients who are
on maintenance treatment with the SSRIs citalopram 20
mg, sertraline 100mg and fluoxetine 20mg. We have also
included mirtazapine 30mg given its increasing use. To-
gether these medications currently comprise about 75% of
all long-term antidepressant prescriptions in England (per-
sonal email communication with Prof. Irene Petersen) and
are all licensed for treatment of depression.
Methods/design
Study design
The ANTLER trial is a double-blind, individually rando-
mised, parallel group controlled trial. We will recruit in-
dividuals in primary care who are currently on one of
four of the most commonly used antidepressant medica-
tions but are currently well enough to consider stopping
medication. Participants will be recruited from primary
care practices in four UK sites: London, Bristol, South-
ampton and York.
Our trial will compare continuing the antidepressant
medication (citalopram 20mg, sertraline 100mg, fluoxetine
20mg or mirtazapine 30mg) with replacement of the
medication with an identical placebo after a tapering
period. The trial intervention will be for 52 weeks and we
will follow up the participants at 6, 12, 26, 39 and 52 weeks.
Inclusion and exclusion criteria
Inclusion criteria
Eligible participants will be primary care patients who are
being treated for depression; have had at least two epi-
sodes of depression; are aged 18–74 years; have been tak-
ing antidepressants for 9months or more and are
currently on citalopram 20mg, sertraline 100mg, fluoxet-
ine 20mg or mirtazapine 30mg; and are well enough to
consider stopping their antidepressant medication. We
have a pragmatic approach to the ‘well enough’ definition
and will not expect to have an accurate timeframe of how
long patients have been feeling well prior to enrolment
into the trial. To be eligible, participants must also have
adhered to their medication. We will use the same criteria
as used in the MIR trial to define adherence using a
five-item self-report measure of compliance [4]; the ques-
tions are available from the authors on request.
Exclusion criteria
Participants will also be excluded if they meet inter-
nationally agreed (ICD-10) criteria for a depressive ill-
ness assessed using the CIS-R. GPs will be asked to
exclude patients who have bipolar disorder, psychotic
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illness, dementia or a terminal illness; are unable to
complete self-administered questionnaires in English;
have contraindications for any of the prescribed medica-
tion; are concurrently enrolled in another investigational
medicinal product (IMP) trial; are women who are cur-
rently pregnant or planning pregnancy or lactating; are
using monoamine oxidase inhibitors; or have allergies to
placebo excipients.
Recruitment of participants
We plan to recruit 479 participants over 2 years from
approximately 200 practices across our four research
centres, based in England, using two methods: record
search and in-consultation recruitment.
Method 1: record search
GP practice staff or NHS employed Clinical Research
Network (CRN) staff will carry out record searches to
identify potentially eligible patients and write to these
individuals so that they can consider joining the study.
The mail-out procedure will involve an initial letter sent
by the GP surgery to the identified patients, followed by
a reminder invitation letter if there is no response.
Those patients who reply positively to the invitation let-
ter will be reviewed by their GP, who will inform the
local Principal Investigator (PI) on inclusion/exclusion
criteria from the patients’ medical notes. The GP could
also decide that the person was unsuitable to take part
in the trial on any other grounds.
Method 2: in consultation
GPs will introduce the trial to suitable patients at con-
sultation and ask for their permission for release of con-
tact details to the study team. The information will be
sent by secure email or fax to the study team. A study
researcher will contact the patient to confirm eligibility
for the trial and arrange the baseline visit.
Screening of potential participants
Patients who have been identified by either method of
recruitment will answer a depressive symptom question-
naire (PHQ-9 [19]) and questions on adherence to medi-
cation either over the phone, by post or by email. The
PHQ-9 score will be used to indicate whether the indi-
vidual is likely to meet the ICD-10 criteria for depressive
illness at baseline, and therefore if the patient scores 15
and above they will not be invited to the baseline assess-
ment. Potentially eligible patients will be invited for a
baseline assessment that will establish any remaining
eligibility criteria. The assessment will take place in
the patient’s home, at their general practice or on
university premises.
Baseline assessment
At the baseline meeting, the researcher will explain the
study in detail and obtain written informed consent for
the baseline assessment. The potential participants will
complete the following assessments: the Clinical Interview
Schedule (CIS-R) [20] to assess ICD-10 criteria for depres-
sion, past medical history questions including any physical
illness contraindications and past psychiatric treatments,
and sociodemographic and other background information.
The participants will be asked for details of their pre-
scribed medication and prior use of antidepressants.
Potential participants who do not have an ICD-10 pri-
mary diagnosis of depression using the CIS-R will be
told that they are potentially eligible to enter the trial
(pending confirmation by PI) and will be asked to pro-
vide further consent for trial participation.
All participants invited to a baseline assessment will
also complete the following questionnaires: depressive
symptoms (PHQ-9), anxiety symptoms GAD-7 [21],
EQ-5D-5L [22] for quality-adjusted life years (QALYs),
adverse effects of antidepressants (a modified Toronto
Side Effects scale) [23], adherence to study medication,
health-related quality of life SF-12, and withdrawal
symptoms based on the DESS [24]. Potential participants
will be asked to perform computerised emotional pro-
cessing tasks [25–27]. Women of child-bearing age will
carry out a pregnancy test.
Once the baseline assessment is complete, final eligi-
bility status will be confirmed by the local PI.
Randomisation procedure and unblinding
Following completion of the baseline assessment and
provision of written consent, participants will be rando-
mised using the automated randomisation service pro-
vided by Sealed Envelope (https://sealedenvelope.com).
The randomisation will be minimised by the four study
centres, the four medications and the severity of depres-
sive symptoms at baseline (two categories measured
using the CIS-R). The dispensing pharmacy (University
Hospitals Bristol Pharmacy) will be informed of the ran-
domised allocation and post the medication by recorded
delivery to either the participant’s home or GP surgery
at regular 8-week intervals. The researcher will send a
letter to the participant’s GP informing them of the pa-
tient’s enrolment into the trial. Trial participants, clini-
cians and all members of the research team will be
blinded to the trial treatment allocation. Participants will
be free to withdraw from the medication at any time.
Together with the study medication, participants will
be provided with a contact card so that any treating clin-
ician can be unblinded to treatment allocation in case of
a medical emergency (‘emergency unblinding’) or early
unblinding to enable treatment decisions. If unblinding
is required, a formal request by a clinician will be made
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to the trial pharmacy (through the 24-h contact number
provided on the contact card) that has a list of the par-
ticipants’ treatment allocations. The treating physician
will manage the medical emergency as appropriate upon
receipt of the treatment allocation.
The PI or delegate will record any breaking of the
code and reasons for doing so on the Case Report Form
(CRF)/data collection tool and in the site file. Where
possible, members of the research team should remain
blinded. Those participants who have not required emer-
gency or early unblinding will be unblinded on comple-
tion of the trial (‘routine unblinding’). This information
will be provided to their GP by the pharmacy; the par-
ticipant will need to consult their GP and any further
treatment can be discussed during that consultation.
The trial team will remain blind to this information and
will not provide further supplies of the trial medication
once participants have been unblinded.
Treatment of participants
At baseline, participants will be taking either citalopram
20mg, sertraline 100 mg, fluoxetine 20 mg or mirtaza-
pine 30mg. They will be randomised either to remaining
on their current medication or to placebo. For those in
the placebo group, in the first month they will take the
same medication at half the dose (citalopram 10mg, ser-
traline 50 mg, or mirtazapine 15 mg). In the second
month they will take half the dose and placebo on alter-
nate days, and from the third month until the end of the
study they will take the placebo. There is no 10 mg cap-
sule for fluoxetine so those taking fluoxetine at baseline
who are allocated to the placebo arm will alternate be-
tween a 20mg tablet and a placebo tablet for 1 month.
During the second month they will take placebo as flu-
oxetine has a long half-life.
The active medication will be encapsulated and the
placebo will be an identical capsule filled with an inert
excipient. All capsules will exactly match in dimensions
and appearance, so that allocation concealment and
blinding is maintained.
Subsequent assessments
Follow-up assessments will be carried out at 6, 12, 26,
39 and 52 weeks after randomisation. Participants will
continue to be invited to follow-up assessments unless
they have withdrawn from the trial. Participants will be
followed up if they have stopped taking the study medi-
cation. Follow-up assessments will take place either at
the participant’s home, at the general practice or on
university premises. The dates of the assessments will
be recorded and the analysis plan will include mea-
sures to investigate any influence of the timing of the
follow-up appointments.
Follow-up assessment schedule
At 6 weeks post randomisation, the participants will be
asked to complete a postal questionnaire.
At 12, 26, 39 and 52 weeks after randomisation, the
participants will be asked to attend an appointment with
the researcher.
After 52 weeks, primary healthcare use data (pre-
scribed medication, primary care visits) for the time
period of the trial and for 6 months preceding the trial
will be extracted from GP electronic health records.
The follow-up schedule is summarised in a flow-
chart (Fig. 1).
We will examine the test–retest reliability of the
PHQ-9, GAD-7, retrospective CIS-R, adverse effects,
withdrawal symptoms (we have included a scale consist-
ing of 15 items) and adherence questionnaires. The par-
ticipants will be asked to repeat those questionnaires at
one of the follow-up appointments.
At the end of the 52 week follow-up period or on with-
drawal from the study, participants will be advised to see
their GP to discuss their continued treatment (Table 1).
Mechanistic outcomes
We included three computerised emotional processing
tasks (described in the following) to investigate the
neuropsychological markers of antidepressant action. It
has been consistently found [26, 28, 29] that antidepres-
sants acutely affect performance even in healthy volun-
teers on emotion processing tasks, even though there is
no subjective awareness of any change or improvement
of mood. These markers of antidepressant response
could be a factor that might be useful in predicting the
likelihood of relapse.
The word recall task [26] tests memory of socially re-
warding and socially critical information. The participant
is presented with 20 likeable (e.g. cheerful, honest) and 20
dislikeable (e.g. untidy, hostile) personality characteristic
words on a laptop screen in a random order for 500 ms.
Words are matched according to length, usage frequency
and meaningfulness, and they differ at each time point.
After each word, participants indicate whether they would
‘like’ or ‘dislike’ to hear someone describing them in this
way by pressing a key on the keyboard. At the end of the
task, participants are asked to recall as many words as
possible in 2 min. This is a surprise recall task (at base-
line), to test incidental memory. The number of positive
and negative words accurately recalled (hits) and the num-
ber of false responses (intrusions) are also recorded.
In the go–no-go task [25], each trial includes three
events: the presentation of a fractal image; the presenta-
tion of a target; and a probabilistic outcome. At the be-
ginning of each trial, one of four possible fractal images
is presented on a computer screen, which indicates
whether the best choice in a subsequent target detection
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task is a go (pressing a key on the keyboard) or a no-go
(withholding a response to the target). The fractal also
indicates the valence of any outcome dependent on the
participant’s behaviour (reward/no reward or punish-
ment/no punishment). The meaning of fractal images
(go to win, no-go to win, go to avoid punishment, no-go
to avoid punishment) is randomised across participants,
and participants have to learn these by trial and error.
Participants are informed that the correct choice for
each fractal image is either a go (button press) or a
no-go (withhold button press). Actions are required in
response to a target circle that follows the fractal image.
After a brief delay, the outcome is presented (an upward
arrow indicates a win, a downward arrow indicates a loss
and a horizontal bar indicates the absence of a win or a
loss). On go-to-win trials, a button press is rewarded; on
Fig. 1 Summary of the baseline and follow-up schedule for the ANTLER trial. ANTLER ANTidepressants to prevent reLapse in dEpRession, CISR
Clinical Interview Schedule—Revised, DESS Discontinuation-Emergent Signs and Symptoms, EQ-5D-5L EuroQol 5D-5L, GAD-7 Generalized Anxiety
Disorder-7, GP general practitioner, PHQ-9 Patient Health Questionnaire-9, SF-12 Short Form-12
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Table 1 Full schedule of questionnaires used in the ANTLER trial
ANTLER ANTidepressants to prevent reLapse in dEpRession, CISR Clinical Interview Schedule—Revised, DESS Discontinuation-Emergent Signs and Symptoms, EQ-
5D-5L EuroQol 5D-5L, GAD-7 Generalized Anxiety Disorder-7, GP general practitioner, PHQ-9 Patient Health Questionnaire-9, SF-12 Short Form-12
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go to avoid punishment, a button press avoids punish-
ment; in no-go to win, withholding a button press is
rewarded; and in no-go to avoid losing trials, withhold-
ing a button press avoids punishment. The task consists
of 240 trials in total (60 trial per condition). The partici-
pant can win between £1 and £10.
For the face task, prototypical ‘happy’ and ‘sad’ com-
posite images were generated from 20 individual male
faces showing a happy facial expression and the same in-
dividuals showing a sad expression from the Karolinska
Directed Emotional Faces [30], using established tech-
niques [31]. These were used as end-points of a linear
morph sequence that changed in displayed emotion in-
crementally from unambiguously ‘happy’, through ambi-
guity, to unambiguously ‘sad’. The task has 15 images
and each image is presented three times, resulting in 45
trials in total. Each stimulus is presented for 500 ms and
followed by a pattern mask (250 ms) to disrupt any vis-
ual after images. Participants are required to judge faces
from a morphed sequence as either sad or happy.
The results of the mechanistic outcome will not be pre-
sented in the main trial paper that will describe the pri-
mary and secondary outcomes, because these analyses do
not address the primary aim of the trial, which is the clin-
ical effectiveness and cost-effectiveness of long-term
maintenance antidepressants treatment compared with a
placebo. The mechanistic outcomes will be published in a
separate paper or papers after the main trial results have
been published. The paper(s) will aim to investigate hy-
potheses concerning the mechanism of action of anti-
depressant medication.
Withdrawal of trial participants
Participants can withdraw from the trial at any time for
any reason, without their medical care being affected.
Where possible, data already collected will continue to be
used in the trial and participants who stop taking the trial
medication will be asked if they are still willing to meet
with the researcher and provide follow-up data. Once par-
ticipants have stopped their trial medication, they may not
resume trial treatment. If participants withdraw, the rea-
son for and type of withdrawal will be documented.
If the PI is concerned about the clinical condition of a
patient such that they should not be on a placebo, we
will withdraw that patient from the trial and will advise
them to see their GP to receive appropriate treatment
outside of the trial. The decision to withdraw will be
based on factors such as depressive symptoms and sui-
cidality and any other factor which the GP or PI thinks
makes withdrawal in the best interests of the patient.
Packaging, labelling and dispensing
The labelling of medication packs will be Medicines and
Healthcare Products Regulatory Authority (MHRA)
approved and will conform to Annex 13 of Good Manu-
facturing Practice (GMP) standards and Article 13.3 of
Directive 200/20/EC [32]. Each medication pack will
have a Medicine ID number, randomly generated to en-
sure active and placebo medicine packs are indistin-
guishable. This random number will link the pack label
and tear-off portion containing the unblinded contents
information. The tear-off label will be removed by the
dispensing pharmacy at the point of dispensing.
The manufacturer will ship labelled and numbered
packages to the dispensing pharmacy where the trial
medication will be stored under controlled conditions.
The pharmacy will dispense individual patient packs and
oversee the packaging and posting of those packs. After
randomisation, the participant will receive a pack con-
taining 8 weeks’ supply of the trial medication. The trial
medication will be posted every 2 months.
Full IMP accountability records will be maintained at the
dispensing pharmacy: receipt, dispensing, distribution, return
and destruction records. The receipt of the trial medication
by the participant will be logged by the research team.
Concomitant medication
The participants will already have been taking the anti-
depressant medication for at least 9 months before en-
tering the trial. It is possible that some participants
might be taking medication before entry to the study,
which may have interactions or cautions with their anti-
depressant. If this does occur, the PI will make a clinical
judgement about whether that person should be entered
into the study. We will also notify the participant’s GP in
writing of such cautions or possible interactions.
The only strict contraindication for the antidepres-
sants used in the study is for monoamine oxidase inhibi-
tors, so use of these is excluded.
Adverse events
All adverse events (AEs) (untoward medical occurrence
in a participant, which does not necessarily have a causal
relationship with the treatment) of special interest will
be recorded on a structured AE assessment (i.e. a list of
physical symptoms) that is included in every follow-up
assessment. If a participant consults their GP with a
known AE, this will be recorded in the medical notes
only but not communicated to the PI.
As this trial is a phase IV trial of licensed medications
used within their licensed indication with a well-estab-
lished safety profile, AEs will not be recorded in the CRF
apart from those AEs of special interest included in the
follow-up assessments.
All serious adverse events (SAEs) will be recorded by
researchers on the Sponsor SAE reporting form and re-
ported to the Sponsor within 24 h of their knowledge of
the event. The CI and trial manager will also be
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informed. The CI/PI may contact the patient’s GP, de-
pending upon the nature of the SAE, to obtain more in-
formation regarding the event. The Sponsor will notify
the Research Ethics Committee (REC) and MHRA of all
suspected unexpected serious adverse reactions (SUS-
ARs). SUSARs that are fatal or life-threatening must be
notified to the MHRA and REC within 7 days after the
Sponsor has learned of them. Other SUSARs must be re-
ported to the REC and MHRA within 15 days after the
Sponsor has learned of them.
Trial stopping rules
The trial may be prematurely discontinued by the Spon-
sor, Chief Investigator, Regulatory Authority or Funder
on the basis of new safety information or for other rea-
sons given by the Data Monitoring Committee and/or
Trial Steering Committee regulatory authority or ethics
committee concerned.
The trial may also be prematurely discontinued due to a
lack of recruitment or upon advice from the Trial Steering
Committee, who will advise on whether to continue or
discontinue the trial and make a recommendation to the
Sponsor. If the trial is prematurely discontinued, active
participants will be informed and no further participant
data will be collected.
Statistical analysis
We will follow CONSORT guidelines in analysing the
data and reporting the trial findings (http://www.con-
sort-statement.org/). We will also prepare a CONSORT
flow diagram. This will include the number of patients
randomised to each arm of the trial, and the numbers
who have follow-up data available. Initial analyses will
look at summary statistics for all variables, both overall
and by randomised group. Summary statistics for con-
tinuous variables will be the mean, median, SD, lower
quartile and upper quartile, and will be reported appro-
priately according to distribution.
The primary outcome will be the time in weeks to the
beginning of the first episode of depression after ran-
domisation. The primary outcome will be assessed using
a modified and shortened standardised psychiatric as-
sessment (CIS-R) that will ask the participants retro-
spectively over the previous 3 months and will be used
at follow-up points of 12, 26, 39 and 52 weeks. The
retrospective CIS-R is based on five out of 14 CIS-R sec-
tions (depression, depressive ideas, concentration, sleep
and fatigue), but asked retrospectively about symptoms
at the worst point in the previous 3 months. The assess-
ment also asks participants about the time before the as-
sessment when the symptoms began and this is used to
determine the time to relapse. This shortened CIS-R in-
cludes questions asking about depressive symptoms,
such as restlessness, suicidal thoughts, hopelessness,
feeling low for prolonged periods, unresponsiveness of
mood, retardation, loss of sexual interest, lack of con-
centration, reduced self-esteem and feeling of guilt. An
episode will be defined as those having two or more de-
pressive symptoms included in the retrospective CIS-R
for a period of at least 2 weeks. The precise definition
will be included in the analysis plan.
Frank et al. [33] provided a theoretical conceptualisa-
tion and rationale for definitions of the five stages (re-
sponse, remission, recovery, relapse and recurrence) in
the course of depressive illness. However, in practice it is
challenging to distinguish between relapse and recur-
rence because assessments rely on retrospective recall
and symptoms usually vary over time. We will therefore
not differentiate whether the first episode of depression
after randomisation is a relapse (a return of symptoms
of an ongoing, although suppressed, episode) or recur-
rence (a new episode of depressive disorder).
We propose to analyse the primary outcome using an
exact Cox proportional hazards model (to account for
ties), adjusting for the depressive symptom score from
the CIS-R at baseline. We will undertake further sup-
portive analyses including the minimisation variables as
fixed patient-level explanatory variables.
Baseline predictors of missingness of the primary out-
come will be examined.
The secondary outcomes will be the following:
 Depressive symptoms (PHQ-9) [19].
 Anxiety symptoms (GAD-7) [21].
 EQ-5D-5L for quality-adjusted life years (QALYs) [22].
 Adverse effects: physical symptoms (thought to be
adverse effects of antidepressants) [23]. For each
symptom we will ask the participant about the presence
and frequency of the physical symptom and also
whether they attribute the symptom to the medication.
 Health-related quality of life (SF-12) [34].
 Withdrawal symptoms based on the DESS (15 items) [24].
 Healthcare resource use collected from GP
electronic records and directly from participants.
 Client Service Receipt Inventory (modified) for
healthcare and other resource use.
Secondary outcomes will be analysed for each follow-
up point using mixed-effects linear regression in which
the baseline value and follow-up value will both be out-
comes. The interaction between time and group will be
estimated. Variables indicating time and the randomised
group will be included in the models as fixed effects. We
will conduct a supportive analysis using all observations
for a participant in a further mixed-effects regression
model for each outcome.
A detailed statistical and health economic analysis plan
will be written and signed off by the IDMC for the trial
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before the database is locked. The plan will be logged in
the UCL repository and/or on the ANTLER website.
Economic evaluation
We will calculate the mean incremental cost per quality-
adjusted life year (QALY) gained of antidepressant main-
tenance compared with placebo over 12 months from an
NHS and social care perspective using trial data.
Healthcare resource use will be collected from GP elec-
tronic records and a modified version of the Client Service
Receipt Inventory (CSRI), and will include information on
primary and acute care health service contacts, pharma-
ceutical prescriptions, mental health community and in-
patient service use, social care, employment and welfare
payments. Services will be costed using nationally pub-
lished sources. The cost of antidepressant maintenance
will be calculated for the treatment group. For the primary
analysis, costs will be from the NHS and social care per-
spective. A secondary analysis from the societal cost per-
spective will also be conducted.
QALYs will be calculated as the area under the curve
using utility scores calculated from the EQ-5D-5L [22]
collected at each time point, adjusting for baseline values.
Incremental costs and QALYs will be calculated using
ordinary least squares (OLS) regression and adjusting
for baseline depressive symptom score, baseline costs for
the cost analysis and utility scores for the QALYs.
We will conduct one and two-way sensitivity analyses
for any assumptions made and sub-group analyses as
identified. Missing data will be handled in the same way
as for the statistical analysis, with the primary analysis
being an intention-to-treat analysis and supportive ana-
lyses taking into account assumptions about missing-
ness. Bootstrapping will be used to construct confidence
intervals and a cost-effectiveness acceptability curve of
the probability that antidepressant maintenance is
cost-effective for a range of values of willingness to pay
for a QALY gained.
Justification of sample size
A systematic review by Geddes et al. [10] estimated in
an active group compared with placebo a reduction in
odds of relapse of 70%, Kaymaz et al. [9] 65%, Glue et al.
[11] 65% and NICE [8] 50%. Between 15 and 22% of
those on active drug relapsed in 12months. To detect
the difference between relapse rates of 15% (continu-
ation arm) and 30% (withdrawal arm) (hazard ratio
0.46), or 20% (continuation) and 35% (withdrawal) (haz-
ard ratio 0.52), will require sample sizes of respectively
333 and 383 for 90% power at the 5% significance level.
Allowing for 20% attrition, we therefore propose to re-
cruit 479 participants [35].
Data handling and quality assurance
The trial Sponsor is University College London and
takes primary responsibility for ensuring that the design
of the study meets appropriate standards and that ar-
rangements are in place to ensure appropriate conduct
and reporting. A monitoring plan has been agreed with
the Sponsor. Local PIs will be responsible for the data
quality at their centre. The trial will be run in accord-
ance with Good Clinical Practice (GCP) and current
regulatory guidance. All data will be handled according
to the General Data Protection Regulation (GDPR) 2018
as well as UCL Information Security Policy and Trust
Information Governance Policy. The investigators have
full access to all of the data and are under no restrictions
in their use of the data within the constraints of the rele-
vant legal framework. We are open to approaches from
bona fide researchers to have access to the data where
this is consistent with our ethics and regulatory ap-
provals and the legal framework.
Publication policy
An ANTLER publication policy will be developed and
agreed by co-applicants. The funder will be informed of
the publications before they are submitted to journals.
Publications will conform to the International Commit-
tee of Medical Journal Editors (ICMJE) guidelines for
reporting and authorship.
Ethics and regulatory approvals and reporting
The trial is being conducted in compliance with all ap-
plicable regulatory requirements. The Sponsor has en-
sured that the trial protocol, patient information sheet,
consent form, GP letters and other documents have
been approved by the appropriate regulatory body
(MHRA in the UK) and a main research ethics commit-
tee, prior to any patient recruitment. The protocol and
all agreed substantial protocol amendments have been
documented and submitted for ethical and regulatory
approval prior to implementation. Ethical approval was
obtained from the National Research Ethics Service
committee, East of England—Cambridge South (ref.: 16/
EE/0032). Clinical trial authorisation was given by
MHRA. The trial Sponsor is University College London.
The trial has been registered: EudraCT Number 2015–
004210-26; Protocol Number 14/0647 (version 6.0);
Controlled Trials ISRCTN Registry, ISRCTN15969819.
It is the responsibility of the Chief Investigator/Princi-
pal Investigator or designee at each site to ensure that
all subsequent amendments gain the necessary approval.
This does not affect the individual clinician’s responsibil-
ity to take immediate action if thought necessary to pro-
tect the health and interest of individual patients.
The trial investigators and institutions will permit
trial-related monitoring, audits, REC review and regulatory
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inspections, providing direct access to source data/docu-
ments. Trial participants are informed of this during the in-
formed consent discussion.
Within 90 days after the end of the trial, the CI and
Sponsor will ensure that the main REC and the MHRA
are notified that the trial has finished.
The CI will supply the Sponsor with a summary report of
the clinical trial, which will then be submitted to the MHRA
and main REC within 1 year after the end of the trial.
There is a Trial Steering Committee chaired by Prof.
Allan House of Leeds Institute of Health Sciences. The
other independent members are Dr Geoffrey Wong, Prof.
Jonathan Bisson and Ms Lucy Carr. The Independent Data
Monitoring Committee is chaired by Prof. Chris Dowrick
of University of Liverpool and the other members are Dr
Rafael Perera-Salazar and Prof. Mike Crawford.
Insurance
University College London holds insurance against
claims from participants for injury caused by their par-
ticipation in the clinical trial.
Discussion
To our knowledge, the ANTLER trial will be the first large
trial with a long follow-up of 12months to investigate the
effectiveness of antidepressants as maintenance treatment
for patients who are already on long-term maintenance.
Prof. Dee Mangin and the team carried out a similar trial
in New Zealand in 2008, looking at maintenance vs grad-
ual withdrawal of antidepressants in prevention of depres-
sion recurrence in primary care in patients with unipolar
depressive disorder. The trial’s medication was fluoxetine
and included patients (N = 263) who had been on antide-
pressants for 1 year or longer. It was registered on the
Australian and New Zealand Clinical Trail Registry:
ACTRN12608000613303. The sample size was reduced
after the Christchurch earthquakes in 2010–2011 when a
decision to stop recruitment at the primary site (Christ-
church) was made in consultation with the Data Safety
Monitoring Board—all patients enrolled continued in the
trial in Christchurch and other sites. The results have not
yet been published. The ANTLER trial will provide UK
data on a more representative sample of antidepressants.
Utilising both trials’ data together would create an oppor-
tunity for an individual patient meta-analysis for greater
precision of estimates.
The ANTLER trial looks at the four most commonly
prescribed antidepressants in primary care and these are
off patent and relatively inexpensive. Due to the pharma-
cological similarities, we believe the results of the trial
will be applicable to all major classes of antidepressants.
The results of the trial will address an important as-
pect of current clinical practice, by providing a valid and
generalisable estimate of the clinical effectiveness and
cost-effectiveness of long-term maintenance treatment
with antidepressants in UK primary care. The trial par-
ticipants will be recruited from a wide range of primary
care settings across the four study centres, based in
urban and rural, affluent and deprived areas across the
UK, maximising the external validity of the findings
(Additional file 1).
Trial status
The trial began recruiting participants in March 2017 and
recruitment will be ongoing until the end of February
2019. At the time of writing (September 2018), 370 partic-
ipants have been randomised into the study. It is expected
that data collection will be completed by February 2020.
This article describes protocol version 6 dated 3 August
2017; when all initial approvals (REC, HRA and MHRA)
were received, the protocol was version 2 dated 22 Febru-
ary 2016. Following a substantial amendment, the protocol
was amended with changes in the pharmacy arrange-
ments, changes in Sponsor representative and a 6-week
follow-up added, and it became version 5 dated 18 No-
vember 2016. As a result, when recruitment started the
trial was following protocol version 5; since then it has
been amended once to version 6 dated 3 August 2017:
PHQ-9 assessment was removed from the eligibility cri-
teria and instead is being used more flexibly at the screen-
ing stage to identify potentially eligible patients.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (DOC 116 kb)
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